Definium’s LSD formula produces ‘best data ever seen’ in a pivotal depression trial, CEO says
Definium Therapeutics' LSD-based depression treatment shows promising results in a late-stage trial, driving stock surge.
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
The brief
Definium Therapeutics has reported positive results from its Phase 3 trial of DT120, an LSD-based orally disintegrating tablet for major depressive disorder. Business and health news outlets, including WSJ, Reuters, and Fierce Biotech, are reporting on the development.
The next steps involve further discussions of the topline results. Coverage does not yet specify the timeline for regulatory review or potential market launch.
Synthesized by Archynetys from the headlines below under a strict no-invention contract. ✓ fact-checked: unsupported claims removed (67% supported) Updated 1d ago.
Quick answers
What drug is Definium Therapeutics testing?
Definium Therapeutics is testing DT120, an LSD-based orally disintegrating tablet for major depressive disorder.
What phase is the trial in?
The trial is in Phase 3.
How have investors reacted to the news?
Definium's stock has surged in response to the positive trial results.
Coverage (11)
- Definium’s LSD-based therapy elicits ‘profound’ efficacy in Phase 3 depression trial BioSpace · 2d ago
- Definium Therapeutics (DFTX) Hits New High on Impressive Drug Candidate Trial Yahoo Finance · 2d ago
- Breaking: Definium Lands Positive Phase 3, LSD Candidate Shows Strong Antidepressant Effect Psychedelic Alpha · 2d ago
- 🔎 Under the Radar: Definium Shares Propelled by Strong Psychedelic Results WSJ · 2d ago
- Definium Therapeutics Announces Positive Topline Results from Phase 3 Emerge Study of DT120 Orally Disintegrating Tablet (ODT) in Major Depressive Disorder Business Wire · 2d ago
- Definium's LSD-based drug scores win in key major depressive disorder study FirstWord Pharma · 2d ago
- Definium LSD therapy helped patients with major depression in late-stage trial statnews.com · 2d ago
- DFTX Stock Rallies Ahead Of High-Stakes Phase 3 Depression Drug Trial Results Yahoo Finance · 2d ago
- Definium Therapeutics to Discuss Topline Results from Phase 3 Emerge Study in Major Depressive Disorder on June 22, 2026 Business Wire · 2d ago
- Definium's LSD-based depression pill delivers strong late-stage results, shares surge Reuters · 2d ago
- Definium’s LSD formula produces ‘best data ever seen’ in a pivotal depression trial, CEO says Fierce Biotech · 2d ago
Topics
Related trends
Pfizer Announces Topline Phase 3 Results for Sigvotatug Vedotin in Previously Treated Metastatic Non-Squamous Non-Small Cell Lung Cancer
Pfizer's Phase 3 trial for the lung cancer drug Sigvotatug Vedotin failed to meet its primary endpoint for survival.